SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jonathan Schonsheck who wrote (1619)2/10/1997 9:43:00 AM
From: Richard Mazzarella   of 4342
 
Paracelsian Files Patent Application Covering Use Of Novel
Compounds That Inhibit T-Cell Killing By Aids Virus

Cooperative research now under way with National Cancer Institute (NCI) to evaluate
effectiveness of these novel compounds in NCI's HIV-1 model systems

ITHACA, N.Y., Feb. 10 /PRNewswire/ -- Paracelsian Inc today announced that it has filed a patent application
with the U.S. Patent Trademarks Office in Washington, D.C., relating to inhibiting CD4+ T cell depletion
induced by HIV-1 infected cells.

The human immunodeficiency virus (HIV) infects cells of the immune system known as CD4+ T cells. HIV
infection eventually produces the loss of CD4+ T cells, resulting in the onset of AIDS. Paracelsian scientists
have discovered methods of protecting CD4+ T cells from being destroyed by HIV-1 infected cells.

"These methods may be useful with antiviral therapeutics to prevent loss of CD4+ T cells in HIV-infected
patients," said Dr. John Babish, Paracelsian's vice president and chief science officer. "Preliminary results
indicate that these methods work well in conjunction with additional antiviral pipeline products at Paracelsian."

Paracelsian's Cooperative Research and Development Agreement (CRADA) with the National Cancer
Institute will serve as a platform to study the effectiveness of these methods in NCI's additional HIV-1 model
systems consisting of clinical isolates. This work will provide additional validation of the discoveries made in
Paracelsian's laboratory.

This is the second cellular target discovered by Paracelsian's screening methodology for therapeutic
intervention of CD4+ T cell depletion caused by HIV. Because do not attack the HIV virus directly and act to
correct cellular imbalances caused by HIV, the chances of HIV developing resistance to such therapeutics is
greatly reduced.

Paracelsian is a biotechnology company engaged in the discovery of useful products from herbal sources. Its
discoveries are accomplished by applying the Company's proprietary screening technology, based in signal
transduction, to its library of extracts used in Traditional Chinese Medicine. SOURCE Paracelsian Inc.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News